

| | |
|---|--|
| *Evolent | |
| Clinical guidelines: PROTON BEAM RADIATION THERAPY | Original Date: June 2013 |
| CPT codes: 77520,77522,77523,77525 | Last Revised Date: May 2023 |
| Guideline Number: Evolent_CG_221 | Implementation Date: January 2024 |

GENERAL INFORMATION

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*

Most requests for radiation therapy are addressed by Evolent treatment site clinical guidelines. However, there may be requests that are not. For such requests, determinations will be made on a case-by-case basis utilizing the following guidelines (when applicable) but not limited to: National Comprehensive Cancer Network (NCCN), American Society for Radiation Oncology ASTRO (i.e., Model Policies; Evidence-Based Consensus Statement), ACR Appropriateness Criteria, American Society of Clinical Oncology (ASCO) and/or peer reviewed literature.

MEDICALLY NECESSARY INDICATIONS FOR PROTON BEAM THERAPY (Will be reviewed on a case-by-case basis)

Treatment of the following in children less than 21 years of age

- Primary or benign solid tumors (curative intent; occasional palliative treatment) when sparing of surrounding normal tissues cannot be achieved with photon therapy

Treatment at any age¹

- Primary hepatocellular tumors treated with hypofractionated regimens
- Spinal tumors (primary or metastatic) where spinal cord has previously been treated with radiation or where the spinal cord tolerance may be exceeded with conventional treatment
- Tumors at the base of skull (chordoma, chondrosarcomas)
- Intraocular melanomas or other ocular tumors
- Patients with genetic syndromes making total volume of radiation minimization crucial, such as, but not limited to NF-1 patients and retinoblastoma patients
- Non-metastatic retroperitoneal sarcomas
- Re-irradiation cases (where cumulative critical structure dose would exceed tolerance dose)

- Malignant and benign primary CNS tumors: Consider proton therapy for patients with good long-term prognosis (grade 2 and 3 IDH-mutant diffuse glioma² and 1p19q codeleted tumors³) to reduce acute and late toxicity, especially for tumors located near critical OARs⁴
- Craniospinal RT: To reduce toxicity from CSI in adults, consider the use of IMRT or protons if available (for patients with positive CSF or known metastatic disease)⁵
- Advanced (e.g., T4) and/or unresectable head and neck cancers⁶⁻¹⁷
- Cancers of the paranasal sinuses and other accessory sinuses

OTHER TREATMENT OPTIONS(Will be reviewed on a case-by-case basis)^{1, 4, 18}

For peer review purposes supporting documentation from the radiation oncologist is required and should include the clinical rationale for performing proton beam rather than 3-D conformal or IMRT or SRS.

Proton beam therapy has not been proven to be superior to conventional radiation therapy for all other indications including, but not limited to:

- Prostate cancer
- Breast cancer
- Lung cancer
- Colorectal cancer
- Cervical cancer
- Metastasis
- Gliomas (patients other than long-term prognosis (grade 2 and 3 IDH-mutant tumors [1] and 1p19q codeleted tumors))
- Soft tissue sarcoma (except for non-metastatic retroperitoneal sarcomas)
- Head and Neck (Non-T4 and resectable)
- Pelvic
- Gastric

BACKGROUND

Proton beam therapy (PBT) is a type of external beam radiotherapy that uses charged particles. These particles have unique characteristics including limited lateral spread, scatter, and tissue in a defined range, going for maximum dose delivery over the last few millimeters of the particles' range. The maximum is called the Bragg peak. Proton beam irradiation when applied to treating cancer, uses different proton energy with Bragg peaks at various steps, enabling dose escalation to the tumor, minimizing excess dose to normal surrounding tissue. Over the years, proton beam irradiation has been applied to treating tumors that require dose escalation to achieve a higher probability of cure, as well as tumors requiring increased precision in dose deposition while protecting normal surrounding tissue. Proton therapy has an over 40-year history in treating cancer, yet to date, there have been few

studies that show superiority to conventional photon beam irradiation, especially with modern techniques.

REFERENCES

1. American Society for Radiation Oncology. Model Policies: Proton Beam Therapy. Updated June 2017. Accessed December 6, 2022.
https://www.astro.org/uploadedFiles/_MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/ASTROPBTModelPolicy.pdf
2. Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. *N Engl J Med*. Apr 7 2016;374(14):1344-55. doi:10.1056/NEJMoa1500925
3. Shih HA, Sherman JC, Nachtigall LB, et al. Proton therapy for low-grade gliomas: Results from a prospective trial. *Cancer*. May 15 2015;121(10):1712-9. doi:10.1002/cncr.29237
4. Halasz LM, Attia A, Bradfield L, et al. Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. *Pract Radiat Oncol*. Sep-Oct 2022;12(5):370-386. doi:10.1016/j.prro.2022.05.004 <https://doi.org/10.1016/j.prro.2022.05.004>
5. Brown AP, Barney CL, Grosshans DR, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. *Int J Radiat Oncol Biol Phys*. Jun 1 2013;86(2):277-84. doi:10.1016/j.ijrobp.2013.01.014
6. Holliday EB, Garden AS, Rosenthal DI, et al. Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of intensity-modulated proton therapy and intensity-modulated photon therapy. *International journal of particle therapy*. 2015;2(1):19-28.
7. Holliday EB, Frank SJ. Proton therapy for nasopharyngeal carcinoma. *Chin Clin Oncol*. Apr 2016;5(2):25. doi:10.21037/cco.2016.03.05
8. McDonald MW, Liu Y, Moore MG, Johnstone PA. Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy. *Radiat Oncol*. Feb 27 2016;11:32. doi:10.1186/s13014-016-0600-3
9. Russo AL, Adams JA, Weyman EA, et al. Long-Term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma. *Int J Radiat Oncol Biol Phys*. May 1 2016;95(1):368-376. doi:10.1016/j.ijrobp.2016.02.042
10. Dagan R, Bryant C, Li Z, et al. Outcomes of Sinonasal Cancer Treated With Proton Therapy. *Int J Radiat Oncol Biol Phys*. May 1 2016;95(1):377-385. doi:10.1016/j.ijrobp.2016.02.019
11. Simone CB, 2nd, Ly D, Dan TD, et al. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. *Radiother Oncol*. Dec 2011;101(3):376-82. doi:10.1016/j.radonc.2011.05.028
12. van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. *Oncologist*. 2011;16(3):366-77. doi:10.1634/theoncologist.2010-0171
13. van der Laan HP, van de Water TA, van Herpt HE, et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study. *Acta Oncol*. Apr 2013;52(3):561-9. doi:10.3109/0284186x.2012.692885

14. Widesott L, Pierelli A, Fiorino C, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. *Int J Radiat Oncol Biol Phys*. Oct 1 2008;72(2):589-96. doi:10.1016/j.ijrobp.2008.05.065
15. Kandula S, Zhu X, Garden AS, et al. Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: a treatment planning comparison. *Med Dosim*. Winter 2013;38(4):390-4. doi:10.1016/j.meddos.2013.05.001
16. Jakobi A, Stützer K, Bandurska-Luque A, et al. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. *Acta Oncol*. 2015;54(9):1658-64. doi:10.3109/0284186x.2015.1071920
17. van de Water TA, Lomax AJ, Bijl HP, et al. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. *Int J Radiat Oncol Biol Phys*. Mar 15 2011;79(4):1216-24. doi:10.1016/j.ijrobp.2010.05.012
18. NCCN Guidelines: Treatment by Cancer Type. National Comprehensive Cancer Network (NCCN). Updated 2022. Accessed October 13, 2022. https://www.nccn.org/guidelines/category_1#site

POLICY HISTORY

| Date | Summary |
|--------------|--|
| May 2023 | <ul style="list-style-type: none"> • Edited: Malignant and benign primary CNS tumors: Consider proton therapy for patients with good long-term prognosis (grade 2 and 3 IDH-mutant diffuse glioma² and 1p19q codeleted tumors³) to reduce acute and late toxicity, especially for tumors located near critical OARs. • Added reference: Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline, Halasz et al., Practical Radiation Oncology (2022) 12, 370-386 • Deleted Additional Resources • Removed “physician review” language |
| January 2022 | <ul style="list-style-type: none"> • Under “Treatment at any age” <ul style="list-style-type: none"> ○ Added malignant and benign primary CNS tumors ○ Added craniospinal RT ○ Added advanced (e.g., T4) and/or unresectable head and neck cancers ○ Added cancers of the paranasal sinuses and other accessory sinuses • Under “Other Treatment Options Requiring Physician Review” <ul style="list-style-type: none"> ○ Added Gliomas (patients other than long-term prognosis (grade 3 IDH-mutant tumors [1] and 1p19q codeleted tumors)) ○ Added Head and Neck (Non-T4 and resectable) |

Reviewed / Approved by Clinical Guideline Committee

Disclaimer: *Evolut Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Evolut uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolut Clinical Guidelines. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolut reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. **Members should contact their Plan customer service representative for specific coverage information.***